Louisa Nicola - Peptides, Cancer and the Deadly Habits That Lead to Alzheimer’s | SRS #300

Louisa Nicola, an Australian neurophysiologist and founder of Neuroathletics, joins the show to discuss Alzheimer's disease, brain health, and neurodegeneration. She opens by explaining that 60 million people worldwide currently have dementia, projected to triple by 2050, and that Alzheimer's kills more people annually than breast and prostate cancer combined.

Nicola provides a detailed neuroanatomy lesson using a physical brain model, explaining how the brain's 87 billion neurons are fed by a vascular network that would span 400 miles if unraveled. She emphasizes that the hippocampus — responsible for short-term memory and the first structure to deteriorate in Alzheimer's — is highly susceptible to oxidative stress and reduced blood flow. She explains that gamma brain waves (30–100 Hz) are the first oscillations to deteriorate in neurodegeneration, and that emerging research using 40 Hz light and sound stimulation may help entrain the brain and clear amyloid plaques through the glymphatic system during deep sleep.

A major segment covers the amyloid cascade hypothesis and its massive scientific fraud. In 2003, French neuroscientist Sylvane Lesné published research in Nature claiming amyloid beta-56 was the sole cause of Alzheimer's, earning $7 million in personal grants and directing $300 million per year in NIH funding. In 2022, the research was found to be fabricated — the western blot images were manipulated. This scandal wasted 20 years of research, subjected millions of patients to failed clinical trials, and eroded public trust in Alzheimer's science. Nicola argues that amyloid is actually a naturally occurring antimicrobial peptide the brain releases in response to stress, infection, or inflammation — not the root cause of the disease.

Nicola states that 95% of Alzheimer's cases are driven by lifestyle factors, with only 3–5% attributable to genetic mutations. The APOE4 gene is a risk factor (not a guarantee): one copy raises risk 2–3 fold, two copies raise it 10-fold, and 14-fold for women. She notes Chris Hemsworth carries two copies. A landmark study in Africa showed high APOE4 prevalence but low Alzheimer's rates, attributed to more active lifestyles, better diets, and less technological sedentariness.

The conversation covers women's elevated Alzheimer's risk in depth. Women comprise nearly two-thirds of cases due to longer lifespans and the steep hormonal decline during menopause. Estrogen is revealed to be a neuroendocrine hormone that helps shuttle glucose into brain cells and regulate neural inflammation. Without it, brain cells face an energy crisis — contributing to brain fog, hot flashes, and accelerated neurodegeneration. Nicola discusses hormone replacement therapy (HRT) as safe when using bioidentical hormones, started during perimenopause (ages 42–52), and criticizes the Women's Health Initiative study as fraudulent for using horse-derived synthetic estrogen on post-menopausal women.

Exercise is discussed as the most powerful free intervention. Aerobic exercise triggers BDNF (brain-derived neurotrophic factor), which acts as fertilizer for the brain and can grow hippocampal volume by 2% with just 30 minutes daily. Zone 5 high-intensity exercise produces lactate — a myokine that fuels brain cells and clears circulating tumor cells, downregulating 13 types of cancer. Resistance training releases myokines from skeletal muscle that travel to the brain, help form synapses, grow new hippocampal neurons, and clear amyloid — effects pharmaceutical companies have been unable to replicate synthetically.

Nicola expresses strong opposition to gray-market peptides like BPC-157, explaining that the compound was pulled from clinical trials due to safety concerns and that its mechanism of inducing vascularization could potentially accelerate tumor growth in undetected cancers. She contrasts this with GLP-1 agonists (like Ozempic), which she calls transformative — comparable to the discovery of penicillin — for addressing obesity, insulin resistance, and potentially dementia risk factors.

The shingles vaccine is highlighted as dramatically underappreciated: studies from Wales, Australia, and the US show that receiving it after age 50 reduces all-cause dementia risk by 50%, because the reactivated chickenpox virus triggers amyloid release and neural inflammation. Nicola also discusses creatine (10–20g daily) as a brain energy intervention, citing a pilot study where Alzheimer's patients taking 20g daily showed improved cognition and mood. She supports psychedelic therapy for its BDNF-boosting potential and ability to eliminate depression — itself a modifiable Alzheimer's risk factor — while cautioning against unguided use.